Drug Profile
2-Methoxyestradiol - CASI Pharmaceuticals
Alternative Names: 2ME2; CASI-2ME2; Panzem; Panzem® Capsules; Panzem® NCDLatest Information Update: 24 Jul 2015
Price :
$50
*
At a glance
- Originator Childrens Hospital Boston; Harvard Medical School
- Developer CASI Pharmaceuticals; EntreMed
- Class Antineoplastics; Estradiol congeners; Estrenes; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Hypoxia-inducible factor-1 alpha inhibitors; Lymphocyte inhibitors; Mitosis inhibitors; NFATC transcription factor inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Suspended Autoimmune disorders; Rheumatoid arthritis
- Discontinued Age-related macular degeneration; Breast cancer; Carcinoid tumour; Cardiovascular disorders; Endometriosis; Glioblastoma; Multiple myeloma; Osteoporosis; Ovarian cancer; Prostate cancer; Renal cell carcinoma